Prioritise research on vaccines for pregnant and breastfeeding women

Terra Manca; Françoise Baylis; Flor M. Munoz; Karina A. Top

doi:10.1016/S0140-6736(22)00379-8

Prioritise research on vaccines for pregnant and breastfeeding women

Terra Manca, Françoise Baylis, Flor M. Munoz, Karina A. Top

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	890-893
Number of pages	4
Journal	The Lancet
Volume	399
Issue number	10328
DOIs	https://doi.org/10.1016/S0140-6736(22)00379-8
Publication status	Published - Mar 5 2022
Externally published	Yes

Bibliographical note

Funding Information:
KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(22)00379-8

Cite this

@article{786d6bf55a9847b6ae8a1b1abc434e62,

title = "Prioritise research on vaccines for pregnant and breastfeeding women",

author = "Terra Manca and Fran{\c c}oise Baylis and Munoz, {Flor M.} and Top, {Karina A.}",

note = "Funding Information: KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.",

year = "2022",

month = mar,

day = "5",

doi = "10.1016/S0140-6736(22)00379-8",

language = "English",

volume = "399",

pages = "890--893",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10328",

}

TY - JOUR

T1 - Prioritise research on vaccines for pregnant and breastfeeding women

AU - Manca, Terra

AU - Baylis, Françoise

AU - Munoz, Flor M.

AU - Top, Karina A.

N1 - Funding Information: KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.

PY - 2022/3/5

Y1 - 2022/3/5

UR - http://www.scopus.com/inward/record.url?scp=85125524172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125524172&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)00379-8

DO - 10.1016/S0140-6736(22)00379-8

M3 - Comment/debate

C2 - 35248174

AN - SCOPUS:85125524172

SN - 0140-6736

VL - 399

SP - 890

EP - 893

JO - The Lancet

JF - The Lancet

IS - 10328

ER -

Prioritise research on vaccines for pregnant and breastfeeding women

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Cite this